PeptiDream (4587.T) Stock Price

PeptiDream Price

JPX·CLOSED
1,093.00
​
Market closed

Revenue has compounded at 37.5% per year over the past 18 years to 18.52 B JPY. Earnings per share have grown at 60.7% per year over the last 17 years. PeptiDream's net margin stands at -20.2%, down from 27.3% several years earlier. Analysts set a median price target of 2,856.00 JPY, implying 161.3% above the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

PeptiDream stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PeptiDream business model & stock analysis

PeptiDream Inc is a Japanese biotech company specializing in novel therapeutics and drugs. The company was founded in 2006 by Professor Hiroaki Suga, who established the field of peptide synthesis at the University of Tokyo. Peptides are short chains of amino acids used in pharmaceutical development and diagnosis. PeptiDream uses a patented technology to generate billions of different peptides, which can then be systematically tested for functionality and applicability. The company also utilizes artificial intelligence and machine learning to specifically find compounds that can potentially treat cancer or neurodegenerative diseases. PeptiDream has four diverse business areas focusing on different applications. The first area is the identification of new drugs, where the company collaborates with several pharmaceutical and biotech firms to develop new compounds. The second area focuses on the development of peptide-based diagnostics. An example of this is the PeelAVERT technology, which identifies cancer-causing proteins through a "peeling process" of skin samples. This allows for personalized cancer treatment and improves success rates. The third area involves the development of agrochemicals. PeptiDream aims to replace chemical pesticides with biodegradable peptide-based compounds that have no negative impact on the environment. The fourth area aims to enhance quality of life through the use of peptides. The company focuses on compounds that can strengthen the immune system or slow down the aging process. PeptiDream has made several groundbreaking discoveries, including the PD-1 inhibitor technology for cancer treatment. This method uses peptides to activate the body's immune system and kill cancer cells. PD-1 inhibitors have shown promising results in clinical studies for lung cancer, kidney cancer, and other tumor types. PeptiDream has also developed a technology called "Peptide Discovery Platform System 2.0," which allows for the rapid generation and analysis of billions of diverse peptides. This method has been patented and enables PeptiDream to quickly focus on the development of new compounds. PeptiDream is a global leader in the development of peptide therapeutics and diagnostics. The company has earned an excellent reputation and collaborates closely with various research institutions, pharmaceutical companies, and biotech firms. PeptiDream also invests in training the next generation of scientists and strives to provide the industry and society with new compounds.

Frequently asked questions about PeptiDream

PeptiDream Inc's business model revolves around peptide drug discovery and development. The company utilizes its proprietary Peptide Discovery Platform System (PDPS) to create a wide range of non-standard peptide libraries. These libraries serve as valuable sources for identifying potential drug candidates. PeptiDream collaborates with pharmaceutical and biotech companies, enabling them to access its renowned libraries. This business model allows PeptiDream to generate revenue through licensing and milestone payments. By leveraging their expertise in peptide-based therapeutics, PeptiDream Inc aims to contribute to the development of innovative drugs and enhance treatments for various diseases.

PeptiDream Inc is primarily active in the pharmaceutical industry.

The main competitors of PeptiDream Inc in the market include Zai Lab Limited, AstraZeneca PLC, and Novartis AG.

PeptiDream Inc. is a renowned Japanese biopharmaceutical company specializing in peptide drug discovery and development. Founded in 2006, the company has established itself as a leader in the discovery and development of non-standard peptide therapeutics. PeptiDream employs its unique and proprietary Peptide Discovery Platform System (PDPS) to create a diverse library of potential drug candidates. This platform enables the rapid and efficient identification and optimization of peptide-based drugs. PeptiDream has entered into numerous partnerships with leading pharmaceutical companies globally, leveraging its expertise to explore applications in various therapeutic areas. With its innovative approach and extensive collaborations, PeptiDream continues to make significant contributions to the field of peptide drug discovery and development.

PeptiDream Inc has achieved several significant milestones. The company has successfully developed a unique peptide discovery platform called PDPS (Peptide Discovery Platform System), which enables the rapid and efficient discovery of highly diverse and functional peptide-based therapeutics. PeptiDream Inc has also established numerous collaborations with leading pharmaceutical companies to advance the development of novel peptides for various therapeutic areas. Additionally, the company has received multiple prestigious awards and recognitions for its innovative approaches and contributions to the field of peptide-based drug discovery. PeptiDream Inc continues to make remarkable progress in the discovery and development of peptide therapeutics, solidifying its position as a prominent player in the industry.

PeptiDream Inc is primarily present in Japan and the United States.

PeptiDream Inc represents values of innovation, collaboration, and excellence in the field of peptide therapeutics. The company's corporate philosophy revolves around utilizing its proprietary Peptide Discovery Platform System (PDPS) to develop novel and optimized peptides for drug discovery and development. By leveraging their cutting-edge technology and expertise, PeptiDream Inc aims to advance therapeutic options for various diseases, including cancer, metabolic disorders, and autoimmune conditions. The company emphasizes the importance of partnerships with biopharmaceutical companies, academia, and other stakeholders to accelerate the translation of discoveries into potential life-saving treatments. PeptiDream Inc's commitment to scientific advancement and breakthrough innovation drives its mission to improve global healthcare.

Analysts currently set an average price target of 3,176.57 JPY for the PeptiDream stock (median: 2,856.00 JPY), implying +197.7 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the PeptiDream stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PeptiDream to generate revenue of 32.57 B JPY and earnings per share of 36.50 JPY.

Converted at the current exchange rate, the PeptiDream share trades at 6.23 EUR (1,093.00 JPY).

The PeptiDream share (4587.T) is listed on 2 stock exchanges, including: Tokio (JPX) (4587.T).

The company PeptiDream Inc. is a biopharmaceutical company from Japan specialized in the discovery and development of peptide drug candidates. The company was founded in 2006 and is headquartered in Kawasaki City, Japan. PeptiDream utilizes a proprietary technology platform called Peptide Discovery Platform System (PDPS) to create and optimize specific peptide libraries used for the search of new peptide drug candidates. These peptides offer several advantages over traditional small molecules and proteins, including higher selectivity, efficacy, and stability. The company operates in three business areas: 1. Research and Development: PeptiDream collaborates with multinational pharmaceutical companies to develop new peptide drug candidates for various therapeutic applications. The company has partnerships with leading pharmaceutical companies such as Eli Lilly, Novartis, and Sanofi. 2. Standalone project business: PeptiDream also develops its own peptide drug candidates and conducts pre-clinical and clinical studies to test their efficacy and safety. The company has several programs for the development of peptide drug candidates in the areas of oncology, anti-allergy, and metabolism. 3. Platform technology: PeptiDream also offers its PDPS technology platform as a service. Companies can utilize this platform to quickly and effectively create and optimize their own peptide libraries. PeptiDream has a wide range of products utilized both for partnerships and its own development programs. Some of the products include: 1. PDPS technology: Peptide Discovery Platform System (PDPS) is a proprietary technology platform by PeptiDream. It is a fast and effective method for the creation and optimization of peptide libraries. 2. Peptide drug candidates: PeptiDream has created an extensive peptide library with potential drug candidates for various therapeutic applications. These peptides are used for drug development. 3. Peptides for partners: PeptiDream collaborates with multinational pharmaceutical companies to develop new peptide drug candidates for various therapeutic applications. The company also provides its partners with access to its peptide library and PDPS technology platform. Overall, PeptiDream is an innovative company developing peptide drug candidates for a wide range of therapeutic applications. The company has utilized its PDPS technology platform as a key to success and has established itself as a preferred partner for multinational pharmaceutical companies.

The expected revenue of PeptiDream is 32.57 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PeptiDream is 4.71 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PeptiDream is currently 29.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PeptiDream stock.

The price-to-sales ratio (P/S) of PeptiDream is currently 4.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PeptiDream stock.

The Eulerpool Quality Score for PeptiDream is 3/10.

The ISIN of PeptiDream is JP3836750004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of PeptiDream is A1W0KK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of PeptiDream is 4587.T. The ticker symbol is used to trade PeptiDream shares on the stock exchange.

Fair ValueTerminal
1,103.93 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
144.70 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
JPY
Initial public offering
Jun 11, 2013
ISIN
JP3836750004
Cusip
J6363M109
Sedol
B97SH97
Market capitalization
141.66 B JPYLarge Cap
52-Week Range
PEG
-1.14
P/E ratio
P/Ee 2026
30.06
P/Ee 2027
17.66
P/Ee 2028
14.22
P/Ee 2029
9.53
P/Ee 2030
7.19
P/S
P/Se
4.33
EV/EBIT
—
P/B Ratio
2.75
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-5.47 %
Last updated Nov 21, 2026, 3:35 AM

PeptiDream Ticker

JPX · 4587.TOTC · PPTDF

PeptiDream FIGI

4587:JP · BBG004JMYDG94587:JT · BBG004JMYDH84587:JJ · BBG004JMYDS64587:JE · BBG004JMYDW14587:JI · BBG004JMYDX04587:JU · BBG004JMYDY9PPTDF:US · BBG006Z5JGB8PPTDF:PQ · BBG006Z5JGR1PPTDF:UV · BBG006Z5JGT94587:JW · BBG00875LFL34587JPY:X2 · BBG00JS9JG024587JPY:XB · BBG00JS9JG11

All fundamentals and in-depth analysis of PeptiDream

Our stock analysis for PeptiDream stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PeptiDream. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.